Table 1 Clinicopathologic features of rituximab-treated diffuse large B cell lymphoma patients (N = 103)
Variables | Total n (%) | GCB*n (%) | Non-GCB*n (%) |
|---|---|---|---|
Age, years | Â | Â | Â |
 Mean (range) | 57.7 (14–79) | 60.5 (23–79) | 56.2 (14–78) |
 <60 | 50 (49%) | 13 (35%) | 35 (56%) |
 ≥60 | 53 (51%) | 24 (65%) | 27 (44%) |
Sex | Â | Â | Â |
 Male | 61 (59%) | 23 (62%) | 36 (58%) |
 Female | 42 (41%) | 14 (38%) | 26 (42%) |
Primary site | Â | Â | Â |
 Nodal | 37 (36%) | 14 (38%) | 21 (34%) |
 Extranodal | 66 (64%) | 23 (62%) | 41 (66%) |
Ann Arbor stage | Â | Â | Â |
 I, II | 47 (46%) | 19 (51%) | 27 (44%) |
 III, IV | 56 (54%) | 18 (49%) | 35 (56%) |
IPI group†|  |  |  |
 Low (0–2) | 60 (63%) | 24 (65%) | 33 (60%) |
 High (3–5) | 36 (37%) | 13 (35%) | 22 (40%) |
B symptoms†|  |  |  |
 Absent | 74 (76%) | 31 (84%) | 43 (72%) |
 Present | 24 (24%) | 6 (16%) | 17 (28%) |
ECOG PS†|  |  |  |
 0, 1 | 86 (84%) | 34 (92%) | 49 (80%) |
 ≥2 | 16 (16%) | 3 (8%) | 12 (20%) |
LDH†|  |  |  |
 Normal | 43 (45%) | 14 (39%) | 26 (46%) |
 Elevated | 53 (55%) | 22 (61%) | 30 (54%) |
BM involvement†|  |  |  |
 Absent | 85 (86%) | 34 (92%) | 48 (83%) |
 Present | 14 (14%) | 3 (8%) | 10 (17%) |
Number of extranodal sites | Â | Â | Â |
 0, 1 | 75 (73%) | 26 (70%) | 46 (74%) |
 ≥2 | 28 (27%) | 11 (30%) | 16 (26%) |
EBER†|  |  |  |
 Negative | 95 (94%) | 37 (100%) | 55 (90%) |
 Positive | 6 (6%) | 0 (0%) | 6 (10%) |
Treatment | Â | Â | Â |
 Rituximab + CHOP | 97 (94%) | 37 (100%) | 57 (92%) |
 Rituximab + others | 6 (6%) | 0 (%) | 5 (8%) |